Pharmacogenomic Effect/ADR for Lapatinib (DBSNPE000263)

Identifier
DBSNPE000263
Drug
DB01259 (Lapatinib)
Interacting Gene/Enzyme
HLA class II histocompatibility antigen, DRB1-11 beta chain
Gene Name
HLA-DRB1
UniProt ID
P20039
Defining Change(s)
HLA-DRB1*07Not Available
Allele Name
HLA-DRB1*07:01
Genotype(s)
Not Available
Type(s)
ADR Directly Studied
Groups
Not Available
Description
The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.
References
  1. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR: HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18. [PubMed:21245432]